BC Cancer Foundation - Impact Report 2016 - (Page 6)
research in the Lab
PREDICTING RESPONSE TO TREATMENT
IDENTIFYING
GENETIC MUTATIONS
Today, experts
recognize more than
40 different types of
lymphoid cancers. To
bring more effective,
personalized therapies
to patients, the BC
Cancer Agency's Centre
for Lymphoid Cancer
genomically
sequenced
1,000
lymphoid
cancers
6
IMPACT REPORT 2016
for treatment failure, which may lead to more effective,
life-saving treatments. The study, published in The Lancet
Oncology, proved that the test, called m7-FLIPI, can reliably
predict patient response to existing treatments. Follicular
lymphoma is a subtype of non-Hodgkin lymphoma, and
while effective treatments exist, about 20 per cent of
patients respond poorly or not at all to current
therapies. Identifying the patient whose
treatment is likely to fail from the onset
We
means oncologists can plan alternate,
support
potentially life-saving treatment
800 cancer
researchers at
approaches. Philanthropy made
the Bc cancer
this breakthrough possible.
agency.
TEST REFINES TREATMENT SELECTION
FOR MANTLE CELL LYMPhOMA
Dr. David Scott and his team developed a new test for use by clinicians
treating patients with mantle cell lymphoma. This subtype of non-hodgkin
lymphoma is an aggressive, incurable disease. Patients go through
chemotherapy and stem cell transplants and they're still not being cured-
overall survival is about five years. The new test, MCL55, is a clinical assay
that will provide clinicians with a tool to help determine which patients
would respond to different treatments.
Top Left Icon and illustrations by ThinkStock
this year. This process
helps identify mutations
that cause cancer on a
molecular level. With
donor support, Dr.
Joseph Connors and
Dr. Randy Gascoyne are
leading this research,
hoping to achieve better
results for B.C. patients
in the future.
BC Cancer Agency researchers developed a test that
identifies follicular lymphoma patients at the highest risk
Table of Contents for the Digital Edition of BC Cancer Foundation - Impact Report 2016
BC Cancer Foundation - Impact Report 2016
Contents
Immunotherapy
Research in the Lab
Research in the Clinic
Ride to Conquer Cancer1
Personalized Onco-Genomics
BC Cancer Foundation by the Numbers
Financial Five-Year Summary
Financial Highlights
BC Cancer Foundation - Impact Report 2016
https://www.nxtbook.com/nxtbooks/manifest/bccancer_2018spring
https://www.nxtbook.com/nxtbooks/manifest/bccancer_2017winter
https://www.nxtbook.com/nxtbooks/manifest/bccancer_2017fall
https://www.nxtbook.com/nxtbooks/manifest/bccancer_2017donorreport
https://www.nxtbook.com/nxtbooks/manifest/bccancer_2017spring
https://www.nxtbook.com/nxtbooks/manifest/bccancer_2016winter
https://www.nxtbook.com/nxtbooks/manifest/bccancer_2016fall
https://www.nxtbook.com/nxtbooks/manifest/bccancer_impactreport2016
https://www.nxtbook.com/nxtbooks/manifest/bccancer_2016spring
https://www.nxtbook.com/nxtbooks/mcmurry/bccancer_2015winter
https://www.nxtbook.com/nxtbooks/mcmurry/bccancer_2015fall
https://www.nxtbook.com/nxtbooks/mcmurry/bccancer_2015report
https://www.nxtbook.com/nxtbooks/mcmurry/bccancer_2015spring
https://www.nxtbook.com/nxtbooks/mcmurry/bccancer_2014winter
https://www.nxtbook.com/nxtbooks/mcmurry/bccancer_2014fall
https://www.nxtbook.com/nxtbooks/mcmurry/bccancer_2014report
https://www.nxtbookmedia.com